Medical and sexual comorbidities in urogynaecology in the lifespan: clinical approach

ALESSANDRA GRAZIOTTIN MD
Director, Center of Gynecology and Medical Sexology
H. San Raffaele Resnati, Milan, Italy
Co-Director, Post-graduate Course of Sexual Medicine
University of Florence, Italy

Embriologic affinity, anatomic contiguity, hormonal sensitivity, vulnerability to reproductive, coitus-related and iatrogenic and/or traumatic events (Graziotin, 2006), contribute to the frequent and yet neglected co-morbidity between Urinary Incontinence (UI), Lower Urinary Tract Symptoms (LUTS) and Female Sexual Dysfunctions (FSD), specifically genital arousal disorders (Giraldi & Graziotin, 2006), dyspareunia (Graziottin, 2006) and orgasmic difficulties (Whipple & Graziotin, 2006).

Latent classes analysis of sexual dysfunctions by risk factors in women indicate that urinary tract symptoms have a RR = 4.02 (2.75-5.89) of being associated with arousal disorders (and its most frequently reported associated symptom: vaginal dryness) and a RR=7.61 (4.06-14.26) of being associated with sexual pain disorders (Laumann et al., 1999).

The presentation will discuss this comorbidity in the lifespan perspective, with special focus on predisposing, precipitating and maintaining factors – biological, psychosexual and context-related- the clinician should pay attention to, for a comprehensive diagnosis and a well tailored etiologically oriented treatment (Graziottin & Leiblum, 2005).

The Overactive Bladder (OAB) is a frequent but underreported condition, affecting from 11.4% to 17% of women over 40 year. Fear of rejection, shame, embarrassment, loss of self-esteem, all contribute to the difficulty the woman has in reporting to her own physician and asking for help. Active investigation on the part of the clinician is key to avoid the “collusion of silence” that involves in a common denial both bladder and sexual problems. OAB is a taboo for many patients, as it conveys the fear and the threat of social rejection. Incontinence violates the social request of control, on mental impulses and on basic functions, like micturition, that is expected to be postponed to time and places socially appropriated. Emotional and sexual intimacy may be crippled by OAB: sexual identity, sexual function and sexual relationship may all change for worse. Up to two thirds of affected women report to be less confident in courting and less willing to start a new history; one third prefers not to reach orgasm for fear of leaking when pleasure peaks. More than half the women affected by OAB report their feeling less feminine and less sexually attractive: the smell of urine instead of the “scent of woman” is difficult to be accepted by both men and women. “Feeling wet” not because one is aroused, but because of urinary leakage, may block every possibility of intimacy. Sexual comorbidity is frequent. Dissatisfaction and avoidance of intimacy may be the conclusion of a repeatedly disappointing experience. The criteria for the differential diagnosis between female ejaculation at orgasm and OAB associated leaking at orgasm will be presented, as they are increasingly relevant in the clinician’ practice (Whipple & Graziotin, 2006).

Stress incontinence and its gynecological and sexual co-morbidities will be briefly discussed.

Post-coital cystitis is more frequent in hypoestrogenic conditions (hypothalamic amenorrhea, post- partum amenorrhea, menopause) when the vaginal pH increases; when the pelvic floor is hyperactive; when genital arousal is poor or absent; when irritable bowels symptoms are complained of; when systemic antibiotics have altered the colonic and vaginal ecosystems. Current observational data indicate that 40 to 61 % of women with recurrent cystitis do report dyspareunia when actively asked for this comorbidity (Salonia et Al., 2005). Special focus will be devoted to: 1) the rationale of assessing the vaginal pH, with the implicit evaluation of both the local ecosystems and the estrogenic tissue level in the vagina, and advantages in term of co-treatment of both sexual symptoms and LUTS when topical vaginal treatments are prescribed after the menopause; 2) the importance of assessing the pelvic floor tonus, and the rational of relaxing the hyperactive pelvic floor in recurrent cystitis and associated conditions, such as dyspareunia, vulvodynia (Bachmann et Al, 2006), and constipation. Available treatment outcomes will be presented in detail.

The ultimate goal is to stress the logic of progressing from a well assessed medical and sexual co-morbidity to a woman-centered, cost and QoL saving co-treatment, with a comprehensive and yet easy to practice approach.

References